Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching' by Cantini and Benucci

Bente Glintborg*, Anne Gitte Loft, Emina Omerovic, Oliver Hendricks, Asta Linauskas, Jakob Espesen, Kamilla Danebod, Dorte Vendelbo Jensen, Henrik Nordin, Emil Barner Dalgaard, Stavros Chrysidis, Salome Kristensen, Johnny Lillelund Raun, Hanne Lindegaard, Natalia Manilo, Susanne Højmark Jakobsen, Inger Marie Jensen Hansen, Dorte Dalsgaard Pedersen, Inge Juul Sørensen, Lis Smedegaard AndersenJolanta Grydehøj, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
ISSN0003-4967
DOI
StatusE-pub ahead of print - 20. dec. 2018

Citer dette

Glintborg, Bente ; Loft, Anne Gitte ; Omerovic, Emina ; Hendricks, Oliver ; Linauskas, Asta ; Espesen, Jakob ; Danebod, Kamilla ; Jensen, Dorte Vendelbo ; Nordin, Henrik ; Dalgaard, Emil Barner ; Chrysidis, Stavros ; Kristensen, Salome ; Raun, Johnny Lillelund ; Lindegaard, Hanne ; Manilo, Natalia ; Jakobsen, Susanne Højmark ; Hansen, Inger Marie Jensen ; Dalsgaard Pedersen, Dorte ; Sørensen, Inge Juul ; Andersen, Lis Smedegaard ; Grydehøj, Jolanta ; Mehnert, Frank ; Krogh, Niels Steen ; Hetland, Merete Lund. / Response to : 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching' by Cantini and Benucci. I: Annals of the Rheumatic Diseases. 2018.
@article{534be449a1704e89887642eb58bdfe02,
title = "Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching' by Cantini and Benucci",
keywords = "anti-tnf, DMARDs (biologic), epidemiology, outcomes research",
author = "Bente Glintborg and Loft, {Anne Gitte} and Emina Omerovic and Oliver Hendricks and Asta Linauskas and Jakob Espesen and Kamilla Danebod and Jensen, {Dorte Vendelbo} and Henrik Nordin and Dalgaard, {Emil Barner} and Stavros Chrysidis and Salome Kristensen and Raun, {Johnny Lillelund} and Hanne Lindegaard and Natalia Manilo and Jakobsen, {Susanne H{\o}jmark} and Hansen, {Inger Marie Jensen} and {Dalsgaard Pedersen}, Dorte and S{\o}rensen, {Inge Juul} and Andersen, {Lis Smedegaard} and Jolanta Grydeh{\o}j and Frank Mehnert and Krogh, {Niels Steen} and Hetland, {Merete Lund}",
year = "2018",
month = "12",
day = "20",
doi = "10.1136/annrheumdis-2018-214788",
language = "English",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",

}

Glintborg, B, Loft, AG, Omerovic, E, Hendricks, O, Linauskas, A, Espesen, J, Danebod, K, Jensen, DV, Nordin, H, Dalgaard, EB, Chrysidis, S, Kristensen, S, Raun, JL, Lindegaard, H, Manilo, N, Jakobsen, SH, Hansen, IMJ, Dalsgaard Pedersen, D, Sørensen, IJ, Andersen, LS, Grydehøj, J, Mehnert, F, Krogh, NS & Hetland, ML 2018, 'Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching' by Cantini and Benucci', Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2018-214788

Response to : 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching' by Cantini and Benucci. / Glintborg, Bente; Loft, Anne Gitte; Omerovic, Emina; Hendricks, Oliver; Linauskas, Asta; Espesen, Jakob; Danebod, Kamilla; Jensen, Dorte Vendelbo; Nordin, Henrik; Dalgaard, Emil Barner; Chrysidis, Stavros; Kristensen, Salome; Raun, Johnny Lillelund; Lindegaard, Hanne; Manilo, Natalia; Jakobsen, Susanne Højmark; Hansen, Inger Marie Jensen; Dalsgaard Pedersen, Dorte; Sørensen, Inge Juul; Andersen, Lis Smedegaard; Grydehøj, Jolanta; Mehnert, Frank; Krogh, Niels Steen; Hetland, Merete Lund.

I: Annals of the Rheumatic Diseases, 20.12.2018.

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

TY - JOUR

T1 - Response to

T2 - 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching' by Cantini and Benucci

AU - Glintborg, Bente

AU - Loft, Anne Gitte

AU - Omerovic, Emina

AU - Hendricks, Oliver

AU - Linauskas, Asta

AU - Espesen, Jakob

AU - Danebod, Kamilla

AU - Jensen, Dorte Vendelbo

AU - Nordin, Henrik

AU - Dalgaard, Emil Barner

AU - Chrysidis, Stavros

AU - Kristensen, Salome

AU - Raun, Johnny Lillelund

AU - Lindegaard, Hanne

AU - Manilo, Natalia

AU - Jakobsen, Susanne Højmark

AU - Hansen, Inger Marie Jensen

AU - Dalsgaard Pedersen, Dorte

AU - Sørensen, Inge Juul

AU - Andersen, Lis Smedegaard

AU - Grydehøj, Jolanta

AU - Mehnert, Frank

AU - Krogh, Niels Steen

AU - Hetland, Merete Lund

PY - 2018/12/20

Y1 - 2018/12/20

KW - anti-tnf

KW - DMARDs (biologic)

KW - epidemiology

KW - outcomes research

U2 - 10.1136/annrheumdis-2018-214788

DO - 10.1136/annrheumdis-2018-214788

M3 - Comment/debate

C2 - 30573653

AN - SCOPUS:85058898832

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -